This article refers to:
Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2016. http://dx.doi.org/10.1080/00365521.2016.1250157
When the above article was first published online, the permille (‰) symbol was wrongly inserted as percentage (%) in “Materials and methods” section. This has now been corrected in the article.
Taylor & Francis apologises for this error.